title: CYP2C9*3 allelic variant and bleeding complications.
authors.forename: M S
authors.initials: MS
authors.lastname: Ogg
authors.forename: P
authors.initials: P
authors.lastname: Brennan
authors.forename: T
authors.initials: T
authors.lastname: Meade
authors.forename: S E
authors.initials: SE
authors.lastname: Humphries
mesh_terms: D000483:Alleles; D001189:Aryl Hydrocarbon Hydroxylases; D065729:Cytochrome P-450 CYP2C9; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004311:Double-Blind Method; D005838:Genotype; D006470:Hemorrhage / Q000139:chemically induced / Q000235:genetics*; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000517:prevention & control; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000235:genetics*; D013927:Thrombosis / Q000517:prevention & control; D014859:Warfarin / Q000009:adverse effects* / Q000378:metabolism
chemical_list: D014859:Warfarin; D003577:Cytochrome P-450 Enzyme System; D013250:Steroid Hydroxylases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D039181:Steroid 16-alpha-Hydroxylase